Published in:
Open Access
01-12-2020 | Osteoarthrosis | Perspectives in Rheumatology
Can metabolic profiling provide a new description of osteoarthritis and enable a personalised medicine approach?
Authors:
M. K. J. Jaggard, C. L. Boulangé, G. Graça, U. Vaghela, P. Akhbari, R. Bhattacharya, H. R. T. Williams, J. C. Lindon, C. M. Gupte
Published in:
Clinical Rheumatology
|
Issue 12/2020
Login to get access
Abstract
Osteoarthritis (OA) is a multifactorial disease contributing to significant disability and economic burden in Western populations. The aetiology of OA remains poorly understood, but is thought to involve genetic, mechanical and environmental factors. Currently, the diagnosis of OA relies predominantly on clinical assessment and plain radiographic changes long after the disease has been initiated. Recent advances suggest that there are changes in joint fluid metabolites that are associated with OA development. If this is the case, biochemical and metabolic biomarkers of OA could help determine prognosis, monitor disease progression and identify potential therapeutic targets. Moreover, for focussed management and personalised medicine, novel biomarkers could sub-stratify patients into OA phenotypes, differentiating metabolic OA from post-traumatic, age-related and genetic OA. To date, OA biomarkers have concentrated on cytokine action and protein signalling with some progress. However, these remain to be adopted into routine clinical practice. In this review, we outline the emerging metabolic links to OA pathogenesis and how an elucidation of the metabolic changes in this condition may provide future, more descriptive biomarkers to differentiate OA subtypes.